Cover
Vol. 3 No. 2 (2013)

Published: December 31, 2013

Pages: 15-20

Research Article

Anthropometric, hormonal and biochemical Indices in patients with polycystic ovarian syndrome

Manal T Mutib 1 Farqad B Hamdan 2 Anam R. Al-Salihi
1High Institute of Infertility Diagnosis and Assisted Reproductive Technology, Al-Nahrain University
2Department of Physiology, College of Medicine, Al-Nahrain University
History
  • Received: September 1, 2013
  • Available Online: December 1, 2013

Abstract

Background: Polycystic ovary syndrome is the most common, yet complex, endocrine disorder with principal features of anovulation, amenorrhea, ovulation-related infertility, polycystic ovaries, and obesity. Number of metabolic aberrations is now well recognized as a growing public health problem in PCOS as glucose intolerance, hyperinsulinemia and dyslipidemia. Objective: To investigate and analyze the anthropometric, hormonal profile and metabolic abnormalities of obese and non-obese women with this disorder. Materials and Methods: Sixty-five healthy Iraqi women serves as the control group and eighty-four infertile women divided into two subgroups depending on the BMI (< and ≥30 kg/m2) were studied. BMI, waist to hip ratio and waist to thigh ratio were measured. Serum levels of luteinizing hormone, follicle stimulating hormone, estradiol, testosterone, fasting blood glucose, and oral glucose tolerance test, and total lipid profile were measured. Results: BMI, waist/hip, waist/thigh ratio were significantly higher in PCOS than control women. Lower FSH level, higher LH and E2 levels, LH/FSH ratio, and lower E2/testosterone ratio was found in obese and non-obese PCOS. Higher blood sugar level, high cholesterol, triglyceride, LDL, VLDL and lower HDL levels in PCOS compared to control women. Conclusion: Obesity is a common finding of women with PCOS, but it is not part of the diagnostic criteria. Women with PCOS usually have the so-called centralobesity (Visceral adiposity), and therefore tend to have an increased waist-hip ratio (WHR) and waist to thigh ratio, regardless of the weight factor (i.e., in obese and non-obese). PCOS patients exhibited abnormal hormonal status and biochemical indices also regardless of obesity.

Keywords

References

  1. Asuncion M, Calvo RM, San Millan JL, Sancho J, Avila S, EscobarMorreale HF. A prospective study of the prevalence of the polycystic ovary syndrome in unselected Caucasian women from Spain. J Clin Endocrinol Metab, 2000; 85:24348-
  2. Legro RS, Kunselman AR, Demers L, Wang SC, Bentley-Lewis R, Dunaif A. Elevated dehydroepiandrosterone sulfate levels as the reproductive phenotype in the brothers of women with polycystic ovary syndrome. J Clin Endocrinol Metab, 2002; 87:21348.
  3. Azziz R, Carmina E, Dewailly D. The Androgen Excess and PCOS Society criteria for the polycystic ovary syndrome: the complete task force report. Fertil Steril, 2009; 91:45688-
  4. Carmina E; Rosato F; Janni A; Rizzo M and Longo RA. Relative prevalence of different androgen excess disorders in 950 women referred because of clinical hyperandrogenism. J Clin Endocrinol Metab, 2006; 91(1):26-.
  5. Azziz R, Sanchez LA, Knochenhauer ES, Moran C, Lazenby J, Stephens KC, Taylor K, Boots LR. Androgen excess in women: experience with over 1000 consecutive patients. J Clin Endocrinol Metab, 2004: 89:45362-.
  6. van Hooff MH, Voorhorst FJ, Kaptein MB, Hirasing RA, Koppenaal C, Schoemaker J. Predictive value of menstrual cycle pattem, body mass index, hormone levels and polycystic ovaries at age 15 years for oligo amenorrhoea at age 18years. Hum Reprod, 2004; 19:38392-.
  7. Wood JR, Nelson VL, Ho C, Jansen E, Wang CY, Urbanek M, McAllister JM, Mosselman S, Strauss JF 3rd. The molecular phenotype of polycystic ovary syndrome (PCOS) theca cells and new candidate PCOS genes defined by microarray analysis. J Biol Chem, 2003; 278:2638090-.
  8. Bhathena RK. Insulin resistance and the long -term consequences of polycystic ovary syndrome. J Obstet Gynaecol, 2011; 31:10510-
  9. Tsilchorozidou T, Overton C, Conway GS. The pathophysiology of polycystic ovary syndrome. Clin Endocrinol, 2004; 60:117-.
  10. Lo JC, Feigenbaum SL, Yang J, Pressman AR and Selby JV. Epidemiology and adverse cardiovascular risk profile of diagnosed polycystic ovary syndrome. J Clin Endocrinol Metab, 2006; 91:135763-.
  11. Ehrmann DA, Kasza K, Azziz R, Legro RS, Ghazzi MN. PCOS/ Troglitazone Study Group. Effects of race and family history of type 2 diabetes on metabolic status of women with polycystic ovary syndrome. J Clin Endocrinol Metab, 2005; 90:6671-.
  12. Kaaks R, Lukanova A, Kurzer MS. Obesity, endogenous hormones, and endometrial cancer risk: a synthetic review. Cancer Epidemiol Biomarkers Prev, 2002; 11:15311543-.
  13. Taira M, Hashimoto N. Insulin receptor abnornmalily and its clinical aspect. Nippon Rinsho, 1998; 56:186670-.
  14. Huang A, Brennan K and Azziz R. Prevalence of hyperandrogenemia in the polycystic ovary syndrome diagnosed by the National Institutes of Health 1990 criteria. Fertil Steril, 2010:93(6): 1938-41.
  15. Ewens KG, Jones MR, Ankener W, Stewart DR, Urbanek M, Dunaif A, Legro RS, Chua A, Azziz R, Spielman RS, Goodarzi MO, Strauss JF 3rd. FTO and MC4R gene variants are associated with obesity in polycystic ovary syndrome. PLoS One, 2011; 6(1):16390.
  16. Georgopoulos NA, Saltamavros AD, Vervita V, Karkoulias K,Adonakis G, Decavalas G, Kourounis G, Markou KB, Kyriazopoulou V. Basal metabolic rate is decreased in women with polycystic ovary syndrome and biochemical hyperandrogenemia and is associated with insulin resistance. Fertil Steril, 2009; 92:2505-.
  17. Petersen KF and Shulman GI. Etiology of insulin resistance. Am J Med, 2006; 119 (Suppl. 1) S10-S6.
  18. Saxena P, Prakash A, Nigam A, Mishra A. Polycystic ovary syndrome: Is obesity a sine qua non?A clinical, hormonal, and metabolic assessment in relation to body mass index. J Endocr Metab. 2012; 16:9969-.
  19. Fakhoury H, Tamim H, Ferwana M, Siddiqui IA, Adham M, Tamimi W. Age and BMI Adjusted Comparison of Reproductive Hormones in PCOS. J Fam Med Primary Care, 2012; 1(2):1326-.
  20. Suhail A R and Neuroendocrine Dysfunction in PCOS: A Critique of Recent Reviews. Clin Med Res, 2008; 6(2):4753-.
  21. Iwasa T, Matsuzaki T, Minakuchi M, Tanaka N, Shimizu F. Hirata Y, Kuwahara A, Yasui T, Maegawa M,Irahara M. Diagnostic performance of serum total testosterone for Japanese patients with polycystic ovary syndrome. Endocr J, 2007; 54:2338-.
  22. Martens JW, Geller DH, ArltW, Auchus RJ, Ossovskaya VS, Rodriguez H, DunaifA, Miller WL. Enzymatic activities of P450c17 stably expressed in fibroblasts from patients with the polycystic ovary syndrome. J Clin Endocrinol Metab, 2000; 85 (11): 433846-
  23. Franks S, Stark J, Hardy K. Follicle dynamics and anovulation in polycystic ovary syndrome. Hum Reprod Update, 2008; 14:36778-.
  24. Petry CJ, Ong KK, Michelmore KF, Artigas S, Wingate DL, Balen AH, de Žegher F, Ibáñez L, Dunger DB. Associations between common variation in the aromatase gene promoter region and testosterone concentrations in two young female populations. J Steroid Biochem Mol Biol, 2006; 98(4206-199:(5-.
  25. Willis DS, Watson H, Mason HD, Galea R, Brincat M, Franks S. Premature response to luteinizing hormone of granulosa cells from anovulatory women with polycystic ovary syndrome: relevance to mechanism of anovulation. J Clin Endocrinol Metab, 1998; 83:398491-
  26. Bhathena RK. Insulin resistance and the long-term consequences of polycystic ovary syndrome. J Obstet Gynaecol, 2011; 31:10510-.
  27. Kelley DE. Skeletal muscle triglycerides: an aspect of regional adiposity and insulin resistance. Ann NY Acad Sci, 2002; 967:13545-.
  28. Morales AJ, Laughlin GA, Bützow T, Maheshwari H, Baumann G, Yen SS. Insulin, somatotropic, and luteinizing hormone axes in lean and obese women with polycystic ovary syndrome: common and distinct features. J Clin Endocrinol Metab, 1996. 81(8):285464-.
  29. Dunaif A. Insulin resistance in women with polycystic ovary syndrome. Fertil Steril, 2006; 86:S13-S14.
  30. Goodarzi MO. The Genetic Basis of the Polycystic Ovary Syndrome. In: R. Azziz (ed). Contemporary Endocrinology: Androgen Excess Disorders in Women:Polycystic Ovary Syndrome and Other Disorders, Second Edition. Totowa, NJ. Humana Press Inc.; 2006:p. 22334-.
  31. Cristian-loan I, Nicolae C. and Dan M. Lipid Parameters in Patients with Polycystic Ovary Syndrome. Appl Med Infor, 2012; 31(4):2732-
  32. Gateva A, Kamenov Z. Cardiovascular Risk Factors in Bulgarian Patients with Polycystic Ovary Syndrome and/or Obesity. Obstet Gynecol Int, 2012; Article ID:306347. doi:doi:10.1155306347/2012/
  33. Murray RK, Granner DK, Mayes PA and Rodwell W. Overview of Metabolism. In: Mayes P A and Bender D A (ed). Harper's Illustrated Biochemistry. 26th edition. New York, London, Mexico City: Lange Medical Books/McGraw-Hill; 2003: p.125.
  34. Yasui T, Matsui S, Tani A, Kunimi K, Yamamoto S, Irahara M. Androgen in postmenopausal women. J Med Invest, 2012; 59:1227-.
  35. Wijeyaratne CN, Seneviratne Rde A, Dahanayake S, Kumarapeli V, Palipane E, Kuruppu N, Yapa C,Seneviratne Rde A, Balen AH. Phenotype and metabolic profile of South Asian women with polycystic ovary syndrome (PCOS): Results of a large database from a specialist Endocrine Clinic. Hum Reprod, 2011; 26:20213-.
  36. Villa J, RE P. Adipose Tissue Dysfunction in Polycystic Ovary Syndrome. Curr Diab Rep.2011; 11:17984-.